fda compounding semaglutide enforcement november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our fda semaglutide compounding enforcement november

That means product quality, dosage, and ingredient accuracy can vary widely

These include feeling nauseated, vomiting, diarrhea, upset stomach, headache, dizziness and a complete loss of appetite

Clinical data asks a harder question: what happens after months of treatment, structured follow-up, adverse-event tracking, and statistical comparison with placebo

GLP induced weight & muscle loss has lowered your metabolic rate

They are not available over-the-counter due to the need for medical supervision and monitoring of potential side effects and effectiveness

The effect of probiotic supplementation on systemic inflammation in dialysis patients